Haploidentical hematopoietic stem cell transplantation (hHSCT) from a parent to a child has become well established for pediatric patients with high-risk leukemia in the absence of an HLA-matched donor. [1] [2] [3] [4] In most cases, both parents are eligible and willing to donate stem cells for their child. Which parent is the better stem cell donor depends on transplant modality and in particular on graft manipulation: in T cell-depleted hHSCT (TCD-hHSCT) the mother is the better donor, whereas in nondepleted hHSCT the father is the better donor. 5 In TCD-hHSCT, improved event-free survival and lower risk of relapse were reported for mother-to-child transplantations compared with father-to-child transplantations. 6, 7 In the group of mother-tochild transplantations, transplant-related mortality and incidence of GvHD were markedly lower compared with the father-to-child transplantations. We assumed that pregnancy left an imprint on the mother's immune system, which is beneficial in hHSCT from the child's mother. During pregnancy, a bidirectional cell transfer, from mother to child and vice versa, may result in persisting fetal cells in the mother (fetal microchimerism), which are detectable as long as three decades after birth. 8, 9 Hence, we hypothesized that (i) fetal microchimerism (FM) has a role in hHSCT and that (ii) FM may be influenced by the killer immunoglobulin-like receptors (KIRs) pattern on maternal natural killer (NK) cells and KIR ligands on the child's cells. CD56 bright NK cells make up~70% of the lymphocytes in the decidua during the first trimester of pregnancy and represent the major cell subset interacting with cells of the developing fetus. 10 Not surprisingly, certain maternal KIR/fetal KIR ligand combinations are associated with recurrent spontaneous abortions or preeclampsia.
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In compliance with the regulations of the Institutional Review Board (decision PV4296), we retrospectively analyzed 46 pediatric patients who underwent T cell-depleted hHSCT from a parent between 2003 and 2013 in six German transplant centers. Median age was 5 years (range 4 months-21 years), and indications included malignant as well as nonmalignant diseases (Table 1) . Patients had ALL (n = 10), AML (n = 10), juvenile myelomonocytic leukemia (n = 1), immune deficiencies (n = 8) or myelodysplastic syndrome (n = 4). All patients underwent conditioning with a combination of fludarabine, thiotepa and melphalan as well as serotherapy with OKT3 or antithymocyte globulin before receiving the T cell-depleted graft of granulocyte-CSF mobilized PBSC. None of the patients received cyclophosphamide post transplantation. Median stem cell dose was 10.5 × 10 6 (range 2.2-80.2 × 10 6 ) per kg body weight and median T-cell dose was 4.8 × 10 4 (range 0.6-15.3 × 10 4 ) per kg body weight. Excess DNA of the donor extracted immediately before transplant from peripheral blood was assayed for fetal DNA (in mother-to-child transplantations) and for the donor's KIR pattern as well as the recipient's HLA-C type. First, specific markers were selected for each recipient/ mother pair using an extended panel of human biallelic short insertion/deletion polymorphisms, 12 as well as Y-chromosomespecific sequences. 13 Real-time quantitative PCR (qPCR) was performed using the TaqMan technology (Applied Biosystems, Foster City, CA, USA). To standardize DNA content, a second PCR reaction detecting the human hematopoietic cell kinase gene was carried out in the same well. A volume of 10 μL DNA (containing 200-400 ng DNA) was analyzed in 25 μL reaction mixes using the iTaq Universal Probes Supermix (Bio-Rad, Foster City, CA, USA). Primers and probes were obtained from Eurofins MWG GmbH (Ebersberg, Germany). Fetal cell content was quantified based on ct ( = threshold cycle) values obtained after qPCR. When sufficient DNA was available, we performed 5-10 analyses of each sample at the detection limit of 5 × 10 − 4 to increase sensitivity. Each positive reaction was considered as one hit among the number of cells analyzed in that tube. The level of fetal microchimerism was defined as the number of maternal cells in which one hit was detected, for example, one hit in 300 000 maternal cells is reported as a FM level of 3 × 10 − 5 . FM levels greater than one fetal cell in 250 000 maternal cells were considered as FM positive. KIR genotyping was performed by real-time PCR as described by Alves et al. Overall survival was significantly higher in the group of patients receiving stem cells from their FM + mother compared with the patients grafted from their FM − mother (72% vs 29%, P o 0.007) and in the father-to-child transplantation group (72% vs 50%, P o0.05; Figure 1a ). Causes of death were transplant related in 20% of cases in the FM + group as compared with 30% in the FM − group (P o 0.04; Figure 1b ). There was no case of grade-IV acute GvHD and only one or no case of acute GvHD grade III in all groups (Figure 1e ). Percentages of grade-I+II acute GvHD did not differ significantly among FM + and FM − groups. Most interestingly, looking at the minimal residual disease (MRD)-negative acute leukemia patients undergoing first allogeneic HSCT for standard indications, overall survival was significantly higher after hHSCT from FM + mothers than from FM − mothers (66% vs 26%, P o 0.05; Figure 1c) , and there was a trend toward lower risk of relapse in the FM + group (25% vs 52%, P o 0.6; Figure 1d ). Reasons for persistence of fetal cells in some, but not all mothers, are controversial. Although fetal microchimerism is detected during pregnancy and early after delivery in almost all mothers, it is reported to decrease below the detection limit in many mothers over time. In our cohort, we found no correlation of FM with age or gender of the respective child ( Supplementary  Figures 1A and D) . Another possible influence on persistence of FM may be exerted by the KIR receptor/ligand constellation between mother and child. Several studies [15] [16] [17] [18] [19] [20] reported on the impact of NK alloreactivity, or KIR and HLA-C genotype on the outcome of HLA-mismatched transplantations. To our knowledge, the impact of fetal HLA alleles and maternal KIR genotype or phenotype on the development and persistence of fetal Letter to the Editor microchimerism in mothers has not been analyzed yet. We hypothesized that interaction of KIRs with their cognate ligands may influence the survival of fetal cells in the maternal circulation. Therefore, we grouped the children into HLA-C1 homozygous, C1/C2 heterozygous and C2 homozygous, and correlated these groups with the level of FM in the corresponding mother. A higher average FM could be seen in the heterozygous group compared with the C1 homozygous group (Figure 1f) . Furthermore, mothers expressing KIR2DS1 showed a significantly higher level of FM compared with those negative for this activating KIR (Supplementary Figure 1E) . These findings suggest a certain role for KIR and HLA-C on the persistence of fetal microchimerism in mothers. Taken together, there was some correlation between FM and KIR/KIR ligand constellations, but not an identical predictive effect on outcome of hHSCT. Consequently, additional mechanisms allowing for FM are most likely involved. The mechanism by which high levels of FM led to better survival particularly in leukemia patients remains unknown. One could speculate that donor T cells, which are continuously exposed to healthy cells of recipient origin before transplant, are tolerant for physiological Ags of the child, because the cell exchange took place at a time when no leukemic blasts were present. After transplantation, donor T cells may be more effective in detecting and targeting leukemia-associated Ags. This kind of graft-versusleukemia response against a limited set of Ags may be more effective than the alloreaction, which is driven by a large number of Ags and is less restricted to leukemic blasts.
In conclusion, the existence of fetal microchimerism may be a helpful tool to identify the best suitable stem cell donor in hHSCT from a parent. If fetal microchimerism is not detectable, evaluation of KIR/KIR ligand constellations may help to identify the better donor. A prospective study is required to develop and validate an algorithm integrating information on HLA, KIR and fetomaternal microchimerism.
